Page 19 - Delaware Medical Journal August 2015

SCIENTIFIC ARTICLE
Regardless of the ultimate fate of lomitapide and mipomersen, the advances in genetics based pharmacology used to develop these drugs with novel mechanisms of action demonstrates great promise for the future of lipidology. They represent only two examples
of the many unique classes of lipid lowering medications on the horizon. Among these are a unique class of medications known as the proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors, which are currently being studied in late phase clinical trials in both HeFH and HoFH patients. Similar to statins, the PCSK9 inhibitors lower LDL cholesterol through upregulation of the LDL receptor by preventing it’s degradation in the lysosome. While lomitapide and mipomersen are currently labeled only for HoFH patients, the technology used in their development has
the potential to forever change the approach to lipid lowering in hypercholesterolemic patients of all types.
CONTRUBUTING AUTHORS
■ JEFFREY A. MARBACH, MBBS is an Internal Medicine Resident at Thomas Jefferson University Hospitals in Philadelphia, Penn.
■ JHAPAT THAPA, MD is a Cardiovascular Disease Specialist in practice at The Heart Failure Program at Christiana Care Health System in Newark, Del.
■ EDWARD GOLDENBERG, MD, FACC is Director of Preventive Cardiology at Christiana Care Health System in Newark, Del.
■ DANIELLE DUFFY, MD, FACC is a Cardiologist in the Division of Cardiology at the Sidney Kimmel Medical College at Thomas Jefferson University in Philadelphia, Penn.
REFERENCES
1. Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, National Lipid Association Expert Panel
on Familial Hypercholesterolemia. Familial hypercholesterolemias: Prevalence, genetics, diagnosis and screening recommendations from the national lipid association expert panel on familial hypercholesterolemia. J Clin Lipidol. 2011;5:S9-17.
2. Goldberg AC, Hopkins PN, Toth PP, et al.
Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: Clinical guidance from the national lipid association expert panel on familial hypercholesterolemia.
J Clin Lipidol. 2011;5:S1-8.
3. Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis. 2003;168:1-14.
4. Mortality in treated heterozygous familial hypercholesterolaemia: Implications for clinical management. Scientific steering committee on behalf of the simon broome register group. Atherosclerosis. 1999;142:105-112.
5. Mabuchi H, Koizumi J, Shimizu M, et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-apheresis study group. Am J Cardiol. 1998;82:1489-1495.
6. Pfohl M, Naoumova RP, Klass C, et al. Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy. J Lipid Res. 1994;35:1946-1955.
7. Aegerion Pharmaceuticals, Inc. Juxtapid (lomitapide) capsules. Prescribing Information. Cambridge, MA; 2013.
8. Genzyme Corporation. Kynamro (mipomersen sodium) injection. Prescribing Information. Cambridge, MA; 2013.
9. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: A HuGE prevalence review. Am J Epidemiol. 2004;160:407-420.
10. Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HA. Cost effectiveness analysis of different approaches of screening
for familial hypercholesterolaemia. BMJ. 2002;324:1303.
11. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2013.
12. Chaves FJ, Real JT, Garcia-Garcia AB, et al. Genetic diagnosis of familial hypercholesterolemia in a south European outbreed population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol. J Clin Endocrinol Metab. 2001;86:4926-4932.
13. Vohl MC, Szots F, Lelievre M, et al. Influence of LDL receptor gene mutation and apo E polymorphism on lipoprotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia. Atherosclerosis. 2002;160:361-368.
14. Stein EA. Other therapies for reducing low- density lipoprotein cholesterol: Medications in development. Endocrinol Metab Clin North Am. 2009;38:99-119.
15. Di Leo E, Lancellotti S, Penacchioni JY, et al. Mutations in MTP gene in abeta- and hypobeta- lipoproteinemia. Atherosclerosis. 2005;180:311-318.
16. Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007;356:148-156.
17. Cuchel M, Meagher EA, du Toit Theron
H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381:40-46.
18. Samaha FF, McKenney J, Bloedon LT, Sasiela WJ, Rader DJ. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2008;5:497-505.
19. Yu RZ, Lemonidis KM, Graham MJ, et al. Cross- species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem Pharmacol. 2009;77:910-919.
20. Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation. 2006;114:1729-1735.
21. Akdim F, Visser ME, Tribble DL, et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia.
Am J Cardiol. 2010;105:1413-1419.
22. Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation. 2012;126:2283-2292.
23. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:998-1006.
Del Med J | August 2015 | Vol. 87 |
No. 8
243